Neuroprotective Potential of Withania somnifera (Ashwagandha) in Neurological Conditions

  • Rajat SandhirEmail author
  • Abhilasha Sood


Withania somnifera, commonly known as Ashwagandha, is a herb used in the Indian Ayurvedic medical system for centuries for its health benefits in wide range of conditions. It has been documented to enhance the functions of the nervous system and improves cognition. Medicinal properties of Withania somnifera are primarily attributed to the presence of active constituents known as withanolides. The multimodal beneficial effects of WS and its constituents stem from its property to act as an anti-oxidant, anti-inflammatory, anti-cancer, hemopoietic and rejuvenating agent. WS has been shown to have beneficial role in many neurological conditions that include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, anxiety disorders, cerebral ischemia. However, the mechanisms involved in the beneficial effects of WS have not been well understood. The article provides information on the mechanisms involved in neuroprotective ability of WS in preventing various neurodegenerative conditions.


Ashwagandha Cognition Neurodegeneration Withania somnifera Withanolides 


  1. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F (2005) Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol 2:137–147CrossRefGoogle Scholar
  2. Babu PV, Gokulakrishnan A, Dhandayuthabani R, Ameethkhan D, Kumar CV, Ahamed MI (2007) Protective effect of Withania somnifera (solanaceae) on collagen glycation and cross-linking. Comp Biochem Physiol B Biochem Mol Biol 14:308–313CrossRefGoogle Scholar
  3. Baitharu I, Jain V, Deep SN, Shroff S, Sahu JK, Naik PK, Ilavazhagan G (2014) Withanolide A prevents neurodegeneration by modulating hippocampal glutathione biosynthesis during hypoxia. PLoS One 9:e105311CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bhattacharya SK, Bhattacharya D, Sairam K, Ghosal S (2002) Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia. Phytomedicine 9:167–170CrossRefPubMedGoogle Scholar
  5. Bhattacharya SK, Kumar A, Ghosal S (1995) Effects of glycowithanolides from Withania somnifera on an animal model of Alzheimer’s disease and perturbed central cholinergic markers of cognition in rats. Phytother Res 9:110–113CrossRefGoogle Scholar
  6. Bhattarai JP, Park SJ, Han SK (2013) Potentiation of NMDA receptors by Withania somnifera on hippocampal CA1 pyramidal neurons. Am J Chin Med 41:503–513CrossRefPubMedGoogle Scholar
  7. Candelario M, Cuellar E, Reyes-Ruiz JM, Darabedian N, Feimeng Z, Miledi R, Russo-Neustadt A, Limon A (2015) Direct evidence for GABAergic activity of Withania somnifera on mammalian ionotropic GABAA and GABAρ receptors. J Ethnopharmacol 171:264–272CrossRefPubMedGoogle Scholar
  8. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK (2003) Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol 30:399–404CrossRefPubMedGoogle Scholar
  9. Cimarosti H, Henley JM (2008) Investigating the mechanisms underlying neuronal Death in ischemia using in vitro oxygen-glucose deprivation: potential involvement of protein SUMOylation. Neuroscientist 14:626–636CrossRefPubMedPubMedCentralGoogle Scholar
  10. De Rose F, Marotta R, Poddighe S, Talani G, Catelani T, Setzu MD, Solla P, Marrosu F, Sanna E, Kasture S, Acquas E, Liscia A (2016) Functional and Morphological Correlates in the Drosophila LRRK2 loss-of-function Model of Parkinson’s Disease: Drug Effects of Withania somnifera (Dunal) Administration. PLoS One 11:e0146140CrossRefPubMedPubMedCentralGoogle Scholar
  11. Dhar N, Razdan S, Rana S, Bhat WW, Vishwakarma R, Lattoo SK (2015) A decade of molecular understanding of withanolide biosynthesis and in vitro studies in Withania somnifera dunal: prospects and perspectives for pathway engineering. Front Plant Sci 6:1–20CrossRefGoogle Scholar
  12. Dhuley JN (1998) Effect of ashwagandha on lipid peroxidation in stress-induced animals. J Ethnopharmacol 60:173–178CrossRefPubMedGoogle Scholar
  13. Durg S, Dhadde SB, Vandal R, Shivakumar BS, Charan CS (2015) Withania somnifera (Ashwagandha) in neurobehavioural disorders induced by brain oxidative stress in rodents: a systematic review and meta-analysis. J Pharm Pharmacol 67:879–899CrossRefPubMedGoogle Scholar
  14. Fisher RS, Boas WVE, Blume W, Elger C, Genton P, Lee P, Engel J (2005) Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46:470–472CrossRefPubMedGoogle Scholar
  15. Fritschy JM (2008) Epilepsy, E/I Balance and GABAA Receptor Plasticity. Front Mol Neurosci 1:5CrossRefPubMedPubMedCentralGoogle Scholar
  16. Gautam A, Wadhwa R, Thakur MK (2013) Involvement of hippocampal Arc in amnesia and its recovery by alcoholic extract of Ashwagandha leaves. Neurobiol Learn Mem 106:177–184CrossRefPubMedGoogle Scholar
  17. Grover A, Shandilya A, Agrawal V, Bisaria VS, Sundar D (2012) Computational evidence to inhibition of human acetyl cholinesterase by withanolide a for Alzheimer treatment. J Biomol Struct Dyn 29:651–662CrossRefPubMedGoogle Scholar
  18. Gupta A, Singh S (2014) Evaluation of anti-inflammatory effect of Withania somnifera root on collagen-induced arthritis in rats. Pharm Biol 52:308–320CrossRefPubMedGoogle Scholar
  19. Hinterberger H (1971) The biochemistry of catecholamines in relation to Parkinson’s disease. Aust N Z J Med 1(Suppl 1):14–18CrossRefGoogle Scholar
  20. Homayoun H, Khavandgar S, Dehpour A (2002) The role of α2-adrenoceptors in the modulatory effects of morphine on seizure susceptibility in mice. Epilepsia 43:797–804CrossRefPubMedGoogle Scholar
  21. Isoherranen N, Yagen B, Bialer M (2003) New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr Opin Neurol 16:203–211CrossRefPubMedGoogle Scholar
  22. Jayaprakasam B, Padmanabhan K, Nair MG (2010) Withanamides in Withania somnifera fruit protect PC-12 cells from β-amyloid responsible for Alzheimer’s disease. Phytother Res 24:859–863PubMedGoogle Scholar
  23. Jana CK, Hoecker J, Woods TM, Jessen HJ, Neuburger M, Gademann K (2011) Synthesis of withanolide A, biological evaluation of its neuritogenic properties, and studies on secretase inhibition. Angew Chem Int Ed Engl 50:8407–8411CrossRefPubMedGoogle Scholar
  24. Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53:26–38CrossRefGoogle Scholar
  25. John J (2014) Therapeutic potential of withania somnifera: A report on phytopharmacological properties. IJPSR 5:2131–2148Google Scholar
  26. Kataria H, Wadhwa R, Kaul SC, Kaur G (2012) Water extract from the leaves of Withania somnifera protect RA differentiated C6 and IMR-32 cells against glutamate-induced excitotoxicity. PLoS One 7:1–13CrossRefGoogle Scholar
  27. Kataria H, Wadhwa R, Kaul SC, Kaur G (2013) Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas. PLoS One 8:1–12CrossRefGoogle Scholar
  28. Kataria H, Kumar S, Chaudhary H, Kaur G (2016) Withania somnifera Suppresses Tumor Growth of Intracranial Allograft of Glioma Cells. Mol Neurobiol 53:4143–4158CrossRefPubMedGoogle Scholar
  29. Khodaei M, Jafari M, Noor M (2012) Remedial use of withanolides from Withania coagulans (Stocks) dunal. Adv Lif Sci 2:6–19CrossRefGoogle Scholar
  30. Konar A, Shah N, Singh R, Saxena N, Kaul SC, Wadhwa R, Thakur MK (2011) Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS One 6:e27265CrossRefPubMedPubMedCentralGoogle Scholar
  31. Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M, Komatsu K (2002) Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha. Neuroreport 13:1715–1720CrossRefPubMedGoogle Scholar
  32. Kuboyama T, Tohda C, Komatsu K (2006a) Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration. Eur J Neurosci 23:1417–1426CrossRefPubMedGoogle Scholar
  33. Kuboyama T, Hirata K, Aoki-Kinoshita KF, Kashima H, Yasuda H (2006b) A gram distribution kernel applied to glycan classification and motif extraction. Genome Inform 17:25–34PubMedGoogle Scholar
  34. Kulkarni SK, Akula KK, Dhir A (2008) Effect of Withania somnifera dunal root extract against pentylenetetrazol seizure threshold in mice: possible involvement of GABAergic system. Indian J Exp Biol 46:465–469PubMedGoogle Scholar
  35. Kulkarni SK, Verma A (1993) Protective effect of BR-16A (Mentat), a herbal preparation on alcohol abstinence-induced anxiety and convulsions. Indian J Exp Biol 31:435–439PubMedGoogle Scholar
  36. Kumar A, Kumar R, Rahman MS, Iqubal MA, Anand G, Niraj PK, Ali M (2015) Phytoremedial effect of Withania somnifera against arsenic-induced testicular toxicity in charles foster rats. Avicenna J Phytomed 5:355–364PubMedPubMedCentralGoogle Scholar
  37. Kumar P, Kumar A (2009) Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington’s disease. J Med Food 12:591–600CrossRefPubMedGoogle Scholar
  38. Kumar P, Singh R, Nazmi A, Lakhanpal D, Kataria H, Kaur G (2014) Glioprotective effects of Ashwagandha leaf extract against lead induced toxicity. Biomed Res Int 2014:1–15Google Scholar
  39. Kumar G, Patnaik R (2016) Exploring neuroprotective potential of Withania somnifera phytochemicals by inhibition of GluN2B-containing NMDA receptors: An in silico study. Med Hypotheses 92:35–43CrossRefPubMedGoogle Scholar
  40. Kurapati KR, Atluri VS, Samikkannu T, Nair MP (2013) Ashwagandha (Withania somnifera) reverses beta-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS One 8:1–15CrossRefGoogle Scholar
  41. Luxmini KPAMK, Dharmadasa RM, Samarasinghe K, Muthukumarana PRM (2015) Comparative pharmacognostic study of different parts of Withania somnifera and its substitute ruellia tuberosa. World J Agric Res 3:28–33Google Scholar
  42. Manchanda S, Mishra R, Singh R, Kaur T, Kaur G (2016) Aqueous leaf extract of Withania somnifera as a potential neuroprotective agent in sleep-deprived rats: a mechanistic study. Mol Neurobiol. [Epub ahead of print]Google Scholar
  43. Manjunath MJ, Muralidhara (2015) Standardized extract of Withania somnifera (Ashwagandha) markedly offsets rotenone-induced locomotor deficits, oxidative impairments and neurotoxicity in Drosophila melanogaster. J Food Sci Technol 52:1971–1981CrossRefPubMedGoogle Scholar
  44. Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B (2005) Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry (Edgmont) 2:36–41Google Scholar
  45. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazon J (2009) Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules 14:2373–2393CrossRefPubMedGoogle Scholar
  46. More SV, Koppula S, Kim IS, Kumar H, Kim BW, Choi DK (2012) The role of bioactive compounds on the promotion of neurite outgrowth. Molecules 17:6728–6753CrossRefPubMedGoogle Scholar
  47. Nair V, Arjuman A, Gopalakrishna HN, Nandini M (2008) Effect of Withania somnifera root extract on haloperidol-induced catalepsy in albino mice. Phytother Res 22:243–246CrossRefPubMedGoogle Scholar
  48. Olanow CW (2007) The pathogenesis of cell death in Parkinson’s disease – 2007. Mov Disord 22:335–342CrossRefGoogle Scholar
  49. Palliyaguru DL, Singh SV, Kensler TW (2016) Withania somnifera: from prevention to treatment of cancer. Mol Nutr Food Res 1:1–12Google Scholar
  50. Panossian A, Wikman G (2010) Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress—protective activity. Pharmaceuticals (Basel) 3:188–224CrossRefGoogle Scholar
  51. Parihar MS, Hemnani T (2003) Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J Biosci 28:121–128CrossRefPubMedGoogle Scholar
  52. Parihar P, Shetty R, Ghafourifar P, Parihar MS (2016) Increase in oxidative stress and mitochondrial impairment in hypothalamus of streptozotocin treated diabetic rat: antioxidative effect of Withania somnifera. Cell Mol Biol (Noisy-le-grand) 62:73–83Google Scholar
  53. Patil SP, Maki S, Khedkar SA, Rigby AC, Chan C (2010) Withanolide A and asiatic acid modulate multiple targets associated with amyloid-beta precursor protein processing and amyloid-beta protein clearance. J Nat Prod 73:1196–1202CrossRefPubMedPubMedCentralGoogle Scholar
  54. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Perry EK (1999) Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain 122:1449–1468CrossRefPubMedGoogle Scholar
  55. Pingali U, Pilli R, Fatima N (2014) Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants. Pharmacognosy Res 6:12–18CrossRefPubMedPubMedCentralGoogle Scholar
  56. Prakash J, Chouhan S, Yadav SK, Westfall S, Rai SN, Singh SP (2014) Withania somnifera alleviates parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons. Neurochem Res 39:2527–2536CrossRefPubMedGoogle Scholar
  57. Raghavan A, Shah ZA (2015) Withania somnifera: a pre-clinical study on neuroregenerative therapy for stroke. Neural Regen Res 10:183–185CrossRefPubMedPubMedCentralGoogle Scholar
  58. Rai M, Jogee PS, Agarkar G, dos Santos CA (2016) Anticancer activities of Withania somnifera: Current research, formulations, and future perspectives. Pharm Biol 54:189–197CrossRefPubMedGoogle Scholar
  59. Rajasankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, Surendran S (2009a) Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. J Ethnopharmacol 125:369–373CrossRefPubMedGoogle Scholar
  60. Rajasankar S, Manivasagam T, Surendran S (2009b) Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson’s disease. Neurosci Lett 454:11–15CrossRefPubMedGoogle Scholar
  61. Rascol O (2009) “Disease-modification” trials in Parkinson disease: target populations, endpoints and study design. Neurology 72:S51–S58CrossRefPubMedGoogle Scholar
  62. Roshanaei K, Neda NN (2015) Effect of withania somnifera root extract on PTZ-induced seizure threshold in mice. RJFH 10:719–723Google Scholar
  63. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012) Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109:3510–3515CrossRefPubMedPubMedCentralGoogle Scholar
  64. Senthil K, Thirugnanasambantham P, Oh TJ, Kim SH, Choi HK (2015) Free radical scavenging activity and comparative metabolic profiling of in vitro cultured and field grown Withania somnifera roots. PLoS One 10:1–14CrossRefGoogle Scholar
  65. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189CrossRefPubMedPubMedCentralGoogle Scholar
  66. Shinde P, Vidyasagar N, Dhulap S, Dhulap A, Hirwani R (2015) Natural Products based P-glycoprotein Activators for Improved β-amyloid Clearance in Alzheimer’s Disease: An in silico Approach. Cent Nerv Syst Agents Med Chem 16:50–59CrossRefPubMedGoogle Scholar
  67. Singh G, Sharma PK, Dudhe R, Singh S (2010) Biological activities of Withania somnifera. Ann Biol Res 1:56–63Google Scholar
  68. Singh N, Bhalla M, de Jager P, Gilca M (2011) An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med 8(5 Suppl):208–213PubMedPubMedCentralGoogle Scholar
  69. Soman S, Korah PK, Jayanarayanan S, Mathew J, Paulose CS (2012) Oxidative stress induced NMDA receptor alteration leads to spatial memory deficits in temporal lobe epilepsy: ameliorative effects of Withania somnifera and Withanolide A. Neurochem Res 37:1915–1927CrossRefPubMedGoogle Scholar
  70. Soman S, Anju TR, Jayanarayanan S, Antony S, Paulose CS (2013) Impaired motor learning attributed to altered AMPA receptor function in the cerebellum of rats with temporal lobe epilepsy: ameliorating effects of Withania somnifera and withanolide A. Epilepsy Behav 27(3):484–491Google Scholar
  71. Sood A, Kumar A, Dhawan DK, Sandhir R (2016) Propensity of Withania somnifera to attenuate behavioural, biochemical, and histological alterations in experimental model of stroke. Cell Mol Neurobiol 36:1123–1138Google Scholar
  72. Tiwari R, Chakraborty S, Saminathan S, Dhama K, Singh SV (2014) Ashwagandha (Withania somnifera): Role in safeguarding health, immunomodulatory effects, combating infections and therapeutic applications: A review. J Biol Sci 14:77–94CrossRefGoogle Scholar
  73. Tohda C, Joyashiki E (2009) Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET. Br J Pharmacol 157:1427–1440CrossRefPubMedPubMedCentralGoogle Scholar
  74. Trigunayat A, Raghavendra M, Singh RK, Bhattacharya AK, Acharya SB (2007) Neuroprotective effect of Withania somnifera (WS) in cerebral ischemia-reperfusion and long-term hypoperfusion induced alterations in rats. J Nat Remedies 7:234–246Google Scholar
  75. Uddin Q, Samiulla L, Singh VK, Jamil SS (2012) Phytochemical and pharmacological profile of Withania somnifera dunal: A review. J App Pharmaceu Sci 2:170–175Google Scholar
  76. Upadhyaya L, Tiwari AK, Agrawal A, Dubey GP (1990) Role of an indigenous drug geriforte on blood levels of biogenic amines and its significance in the treatment of anxiety neurosis. Act Nerv Super 32:1–5Google Scholar
  77. Vareed SK, Bauer AK, Nair KM, Liu Y, Jayaprakasam B, Nair MG (2014) Blood–brain barrier permeability of bioactive withanamides present in Withania somnifera fruit extract. Phytother Res 28:1260–1264CrossRefPubMedGoogle Scholar
  78. Yin H, Cho DH, Park SJ, Han SK (2013) GABA-mimetic actions of Withania somnifera on substantia gelatinosa neurons of the trigeminal subnucleus caudalis in mice. Am J Chin Med 41:1043–1051CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of BiochemistryPanjab UniversityChandigarhIndia

Personalised recommendations